24 January 2020
Appendix 3B
30 December 2019
Commencement of phase 1 trial for AZD0466 utilising DEP®
16 December 2019
Starpharma receives $4.9M R&D tax incentive refund
10 December 2019
DEP® cabazitaxel progresses to phase 2 on positive results
4 December 2019
Appendix 3B
4 December 2019
Change in Director's Interest Notice - J Fairley
21 November 2019
AGM Results
21 November 2019
AGM Chairman’s address and CEO’s presentation
20 November 2019
VivaGel® condom receives regulatory approval in Europe
19 November 2019
2019 AGM details
13 November 2019
UK launch of VivaGel® BV
12 November 2019
Notice of initial substantial holder
31 October 2019
DEP® gemcitabine outperforms Gemzar® in human pancreatic cancer model
30 October 2019
Quarterly Cashflow Report
23 October 2019
Ceasing to be a substantial holder
23 October 2019
Change in substantial holding
18 October 2019
Notice of Annual General Meeting/Proxy Form
17 October 2019
Appendix 3B
8 October 2019
Starpharma to present at US Drug Delivery Conference
1 October 2019
Change in Director's Interest Notice - J Fairley

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.